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AnAlysIs of Cost MInIMIzAtIon of AdAlIMuMAb CoMPAred WIth 
InflIxIMAb for the treAtMent of ulCerAtIve ColItIs In the PublIC 
MArket In MexICo
Pichardo-Piña CA, Sanchez-Casillas JL
AbbVie, Distrito Federal México, Mexico
Objectives: Determine whether adalimumab reduces costs for the public health 
sector in the treatment of moderate to severe active ulcerative colitis in adult 
patients who have had an inadequate response to conventional therapy in com-
parison with infliximab. MethOds: Adalimumab was considered comparable 
with infliximab in the treatment of Ulcerative Colitis through a systematic review 
of the literature. A cost minimization analysis was then considered appropriate 
under the perspective of the public health care system in Mexico and a time 
horizon of five years. Direct drug and administration costs were considered. 
Univariate and multivariate probabilistic sensitivity analyses were performed. 
Finally, we assessed the budget impact of potential savings. Results: The model 
Resultsshowed that the cost with adalimumab treatment for five years (using an 
annual discount rate of 5%) is $ 96,365.87 (11.2%) lower than the total cost with 
infliximab. This generates savings to the health system. Resultshave a high sensi-
tivity to patient weight, but expected costs in all simulated populations are lower 
with adalimumab. In the base case, the present value of the 5-year budget impact 
with a discount rate of 5% represents savings around $ 348,748,074.14 pesos if 
adalimumab is used in 100% of estimated prevalence in Mexico. cOnclusiOns: 
Adalimumab proved to be an alternative that minimizes expected costs under 
the investigated scenarios given the evidence of comparable efficacy versus inf-
liximab. Also, savings allow greater access to care for patients with UC, benefiting 
the health institution, not only by improving the quality of care with an innova-
tive therapy but also by allowing significant savings that could be used to treat a 
larger number of patients.
GAstroIntestInAl dIsorders – Patient-reported outcomes & Patient  
Preference studies
PGI9
AssessMent of CoMPleMentAry And AlternAtIve MedICIne use In 
hePAtItIs-C PAtIents In QuettA, PAkIstAn
ul Haq N, Shah A, Iqbal Q, Naseem A, Akram A, Mohammd S
University of Balochistan, Quetta, Pakistan
Objectives: The Study Was Conducted to evaluate the use of complementary 
and alternative medicine in Hepatitis-C patients In Quetta, Pakistan MethOds: 
A cross sectional study was conducted from March to September, 2014. Hepatitis-C 
patients having confirm diagnosis visiting different facilities in Quetta city for 
the treatment of their disease, were included in the study. The data was collected 
by use of pre-validated tool made specifically for this study. The descriptive sta-
tistics was used to present the demographic and disease related information. All 
analyses were performed using SPSS 20.0. Results: A total of 389 patients were 
registered in different health facilities of the study out of which 284 patients 
agree to participate in the study. One hundred and seventy two (60.5 %) were 
using complementary and alternative medicine for the treatment of their disease 
along with conventional therapy, Herbal treatment was majorly practiced (41.9 
%) complementary and alternative method, followed by religious Methods(35.0 
%). One hundred and thirty two (76.7 %) of these consult a complementary and 
alternative medicine practitioner. Majority (N= 154, 90%) of the respondents were 
satisfied with the Complementary and Alternative Medicine Methodsthey used 
for treatment of Hepatitis C. cOnclusiOns: The findings of the study show that 
the use of Complementary & Alternative Medicine is prevalent in Hepatitis-C 
patients in Quetta, Pakistan. People satisfied with the use of Complementary 
& Alternative Medicine methods. Further research is needed to evaluate the 
reasons and outcomes for Complementary & Alternative Medicine use by 
patients.
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A hePAtIte C CrônICA dIMInuI A QuAlIdAde de vIdA?
Perlin CM, Borba HH, Wzorek LF, Piazza T, Madeira C, Pontarolo R, Wiens A
Universidade Federal do Paraná, Curitiba, Brazil
ObjetivOs: Verificar se há diferença na qualidade de vida entre pacientes por-
tadores da hepatite C que estão em tratamento (com interferon peguilado mais 
ribavirina associado ou não a um inibidor de protease) com aqueles que não estão 
em tratamento. MétOdOs: Estudo observacional, transversal mediante a apli-
cação de 3 questionários auto-administráveis sendo dois genéricos: Short Form 36 
Questionnaire (SF-36) e Euroqol 5D (EQ-5D) e um específico para doenças hepáti-
cas: Chronic Liver Disease Questionnaire (CLDQ). Os questionários foram aplicados 
em pacientes com hepatite C após a aprovação pelo Comitê de Ética do Hospital de 
Clínicas da Universidade Federal do Paraná e da Secretaria Municipal de Saúde de 
Curitiba, Paraná. Os pacientes assinaram o termo de consentimento livre esclare-
cido (TCLE). Os dados coletados foram tabelados no programa Microsoft Excel 2013 
e a análise estatística feita pelo programa Minitab® 17. ResultAdOs: Através da 
prova de Mann-Whitney (IC 95%), obteve-se diferença estatisticamente signifi-
cante (p< 0,05) no SF-36 nos domínios aspectos físicos e aspectos emocionais assim 
como no CLDQ nos domínios: fadiga, sintomas sistêmicos, atividades, função 
emocional. Não houve tal diferença (p< 0,05) no EQ-5D, porém o valor utility médio 
para pacientes em tratamento foi de 0,661 e para os não tratados 0,733 assim 
como o valor médio da escala analógica visual (VAS) sendo respectivamente 0,57 
e 0,73. cOnclusões: A administração de questionários genéricos com o suporte 
de um questionário específico, que é sensível a aspectos peculiares da doença, 
evidencia que o tratamento tem uma influência negativa na qualidade de vida dos 
pacientes com hepatite C denotando um maior cuidado no manejo dos mesmos 
pela equipe de saúde.
Objectives: To estimate the direct costs of HCV management for genotype 1 
patients throughout their lifetime based on the natural history of the disease from 
payer perspective in Colombia MethOds: Direct costs were estimated from a 
payer perspective by using a micro-costing approach of all relevant resources used 
to manage patients with HCV genotype 1 since the diagnosis for a lifetime perspec-
tive. Resources and clinical practice were identified, measured and valued for nine 
health states. Resource use and clinical patterns were validated with a panel of 
experts in managing HCV patients by applying a comprehensive survey. Each of the 
resources was valued based on standard national public lists of fees in Colombian 
pesos. Total costs for each of the health states of the disease were calculated for 
a one year time horizon Results: Direct cost were presented in US Dollars using 
the average year to date exchange rate (USD 1 = COP 1,974). Estimated average 
direct cost for each health state per year non diagnostic HCV (USD 512), chronic 
HCV F0-F3 (USD 1,440), compensated cirrhosis (USD 976), decompensated cirrhosis 
(USD 10,782), hepatocellular carcinoma (USD 10,263), liver transplantation (USD 
28,883), post-transplant (USD 1,933), monitoring drug therapy for HCV and the 
management of adverse events (USD 1,020), death (USD 15,538). cOnclusiOns: 
Chronic HCV infection represents an important economic and humanistic bur-
den for health systems in the world. This micro-costing study provides valuable 
information for further economic cost of illness analysis from the Colombian 
payers setting. It also reflects severity and economic impact of HCV related health 
states.
PGI5
eConoMIC IMPACt of exPAnded use of bIoloGIC therAPy for Crohn’s 
dIseAse In lAtIn AMerICAn CountrIes
Kotze PG1, Tundia N2, Gumen A3, Macaulay D4, Chaves L2, Bao Y2
1Catholic University of Paraná, Curitiba, Brazil, 2AbbVie Inc., North Chicago, IL, USA, 3Analysis 
Group, Inc., Boston, MA, USA, 4Analysis Group, Inc., New York, NY, USA
Objectives: To estimate the impact on costs resulting from expanded biologics 
use in treating Crohn’s disease (CD) in Latin America over 10 years. MethOds: The 
influence of increasing biologics use for CD therapy during 2013–2023 was mod-
eled from a societal perspective. The model incorporated current and projected 
changes in medical (inpatient and outpatient services), indirect (productivity loss), 
and drug costs; population size; gross domestic product; and CD prevalence. Costs 
associated with expanded biologics use (estimated annual rate of increase 7.41%, 
21.07%, and 4.97% in Brazil, Colombia, and Mexico, respectively) were compared 
with non-expanded use (no increase from 2013 levels). The expanded-use sce-
nario incorporated additional drug costs and benefits (medical and indirect cost 
reduction) attributed to expanded biologics use. Average annual per-patient costs 
of CD therapy and cost offsets based on biologics use were aggregated with base 
annual medical and indirect costs to estimate total cost per patient. Total per-
country annual costs were estimated using population size and CD prevalence. 
Costs were adjusted to currency year 2013. Sensitivity analyses of model inputs 
(CD prevalence and growth of prevalence) assessed model robustness. Results: 
Expanded biologics use was associated with slower annual cost growth vs. non-
expanded use; projected per-patient 2023 costs were R$19,689 vs. R$22,235 in 
Brazil, COP$15.70 million vs. COP$18.66 million in Colombia, and MXN$76,353 
vs. MXN$82,170 in Mexico. Differences were driven by greater medical and indi-
rect cost offsets with expanded vs. non-expanded use (e.g., R$4,390 vs. R$2,148 
[medical] and R$6,723 vs. R$3,290 [indirect]). Expanded biologics use resulted in 
10-year cumulative net cost savings of R$0.08 billion in Brazil, COP$503 billion in 
Colombia, and MXN$1.8 billion in Mexico. cOnclusiOns: Increasing biologics 
use to treat CD may limit cost growth over time by reducing medical and indirect 
costs. These findings may inform policy decisions regarding biologics use for CD 
in Latin America.
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Custo-efetIvIdAde do tenofovIr PArA o trAtAMento dA hePAtIte b 
CrônICA uMA revIsão sIsteMátICA
Balbinot JC1, Wiens A2, Pontarolo R2, Sanches AC1
1Universidade Estadual do Oeste do Paraná, Cascavel, Brazil, 2Universidade Federal do Paraná, 
Curitiba, Brazil
ObjetivOs: O objetivo desse estudo foi realizar uma revisão sistemática sobre 
custo-efetividade do tenofovir para o tratamento de pacientes com hepatite B 
crônica. MétOdOs: Foi realizada uma extensiva busca sistemática na literatura 
por meio das bases de dados Pubmed, Scopus, ScienceDirect, Cochrane, Scielo, HTA 
e ISPOR, além da busca manual, de artigos publicados até fevereiro de 2015. As 
estratégias utilizadas foram “cost-effectiveness” OR “cost-utility” AND “hepatitis 
B treatment” AND “tenofovir”. Os estudos incluídos foram referentes a avaliações 
econômicas do tipo custo-efetividade e custo-utilidade em pacientes adultos e 
portadores de Hepatite B crônica. A intervenção utilizada foi o uso de tenofovir 
em comparação às outras alternativas para o tratamento da doença (lamivudina, 
telbivudina, adefovir, entecavir, interferon alfa e interferon alfa peguilado) e/ou 
nenhum tratamento. Os desfechos avaliados foram os custos relacionados com 
as melhorias de saúde (RCEI, AVAQ e AVG). ResultAdOs: Ao total, 1185 artigos 
foram encontrados e apenas 15 atendiam aos critérios de inclusão. O tenofovir foi a 
estratégia mais custo-efetiva em 2/3 dos artigos selecionados. Nos demais estudos, 
o fator limitante para o tenofovir ser classificado como a melhor estratégia, foi 
o seu custo, pois é possível observar que houveram melhorias nos desfechos em 
saúde avaliados, sendo em alguns casos tão efetivo quanto as alternativas domi-
nantes. cOnclusões: Resultados relevantes foram encontrados, sugerindo que 
o tenefovir é o medicamento mais custo-efetivo para o tratamento da hepatite B 
crônica e também como terapia de resgate. O seu baixo risco de desenvolvimento 
de resistência, aliado ao efeito de proporcionar melhorias na saúde em anos de 
vida ganhos e anos de vida ajustados pela qualidade, além de diminuir as taxas 
de incidência de cirrose, hepatocarcinoma celular e transplantes hepáticos refor-
çam esse resultado. Os desfechos demonstrados podem contribuir na tomada de 
decisão do clínico, na busca pela melhor alternativa para o paciente.
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RVR, SVR12 and SVR24 than placebo. There was no difference in the safety of sofos-
buvir and placebo groups for the majority of evaluated outcomes. cOnclusiOns: 
Our meta-analysis indicates promising efficacy and a good safety profile of sime-
previr for both evaluated doses. Data concerning sofosbuvir reveal the benefits of 
this drug in hepatitis C virus genotype 1 treatment, also in safety terms.
PIn4
AssoCIAted fACtors the vIroloGIC suCCess In A GrouP of PAtIents 
WIth huMAn IMMunodefICIenCy vIrus, MAnAGed by A CAre teAM 
InteGrAl, ePs|surA MedellIn 2010-2013
Estrada JI1, Restrepo AM1, Serna JA2, Abad JM1, Segura AM3
1CES University, Medellin, Colombia, 2UPB University, Medellin, Colombia, 3Antioquia University, 
Medellin, Colombia
intROductiOn: the probability of occurrence of virological failure in patients 
diagnosed with HIV in ARV drug treatment of first and second line is 0.15 and 0.46 
respectively, produce the emergence of viral resistance, loss of future schemes, 
increased hospital admissions, disease progression and death. Objectives: To 
determine the associated factors that explain the virological success and the time 
needed to reach it. MethOds: Type of study: retrospective cohort survival analysis. 
Type of patients: belonging to EPS|SURA regional Medellin, diagnosed with HIV and 
exposed to first time antiretroviral therapy. Variables: dependents (virologic suc-
cess and time required to reach it) and independents (sociodemographic, clinical 
and pharmacotherapeutic). Analysis:frequencies, summary measures, and Kaplan 
Meier for the univariate stage, chi square, Student’s t test or Mann-Whitney U 
and Log Rank Test for the bivariate phase, proportional hazards model and mul-
tiple logistic regression in multivariate phase. Results: 97% of patients achieved 
virologic success, needed 209 days (SD±10.14). Patients had a 95% probability of 
achieving virological success in the first 8.5 months. Properly use drugs was asso-
ciated with a shorter time to achieve virologic success HR 2.68 [1.22-5.90] and a 
greater number of problems with drugs was associated with a longer time HR 0.60 
[0.43-0.83]. cOnclusiOns: virological success was higher than the studies found, 
which was obtained in a short time and was maintained throughout the observation 
period. The variables in this study were not associated with virologic success but 
were associated with a shorter time to reach it.
PIn5
utIlIzACIon de AntIbACterIAnos de uso restrInGIdo en PACIentes 
Adultos hosPItAlIzAdos en el hosPItAl lAs hIGuerAs - tAlCAhuAno
Henriquez K1, de La Jara C2, Lopez M3, Cordova P1, Bello H4, Morales León F3, Fernandez 
P1, Villa L1
1Facultad de Farmacia, Universidad de Concepción, Concepción, Chile, 2Unidad de Farmacia - 
Hospital Las Higueras, Talcahuano, Talcahuano, Chile, 3Universidad de Concepcion, Concepcion, 
Chile, 4L. de Investigación en Agentes Antibacterianos - Universidad de Concepción, Concepcion, 
Chile
ObjectivOs: Estudiar la evolución del consumo de antibacterianos de uso restrin-
gido en pacientes adultos hospitalizados durante el periodo 2005 al 2012, en el 
hospital Las Higueras de Talcahuano. MetOdOlOgíAs: Se realizó un estudio ret-
rospectivo durante los años 2005 - 2012, del consumo mensual de antibacterianos 
de uso restringido. Los antibacterianos considerados fueron clasificados según el 
sistema ATC/DDD. Se incluyo vancomicina, carbapenémicos (imipenem, ertapenem 
y meropenem) y cefalosporinas de tercera generación (ceftriaxona, ceftazidima y 
cefotaxima). Se determinó la densidad de consumo expresado en porcentaje y en 
términos del número de DDD/100 días-cama-ocupados. La evolución del consumo 
se determinó calculando diferencia porcentual entre los año 2005 y 2012. La com-
paración de los consumos se realizó con la prueba t-test. Se consideró diferencias 
significativas con un nivel de significancia de p< 0.05. ResultAdOs: Ceftriaxona 
fue el antibacteriano con mayor consumo total (63%) (292,4 DDD/100 días-cama-
ocupados) seguido por vancomicina (17%) (77,13 DDD/100 días-cama-ocupados). 
Por su parte, el servicio de paciente crítico y de cirugía mostraron el mayor con-
sumo de antibióticos, con un total de 150 DDD/100 días-cama-ocupados (54%) y 54 
DDD/100 días-cama-ocupados (20%) respectivamente. En relación a la evolución del 
consumo, se observó un incremento significativo en el consumo de vancomicina 
(+67%; p< 0,05), imipenem (+62%; p= 0.004), meropenem (+84%; p= 0.006) y ceftri-
axona (+44%; p= < 0.05). cOnclusiOnes: El consumo de todos los antibióticos 
estudiados aumento significativamente, especialmente ceftriaxona, vancomicina 
y carbapenémicos. La consecuencia de este consumo pudiera significar un aumento 
de la resistencia bacteriana intrahospitalaria y los costos asociados en la atención 
de salud, por lo que se sugiere su estudio.
PIn6
does use of CAlCIuM ChAnnel bloCkers AffeCt the rIsk of InCIdent 
ACtIve tuberCulosIs dIseAse? A nested CAse Control study on A 
nAtIonAl heAlth ClAIM dAtAbAse
Lee C1, Hsu W2, Chang S3
1National Taiwan University Hospital, Yunlin Branch, Douliou, Taiwan, 2National Taiwan 
University Hospital, Taipei City, Taiwan, 3Chang Gung Memorial Hospital and Chang Gung 
University College of Medicine, Taoyuan City, Taiwan
bAckgROund: It is World Health Organization’s Global Plan to eradicate Tuberculosis 
(TB) disease by the year of 2050, but it is difficult to achieve that goal by the current 
rate of infection decrease. Our goal is to evaluate whether calcium channel blocker, 
an existing cardiovascular drug can affect the onset of active TB. Objectives: To 
evaluate whether the use of different classes of calcium channel blockers (CCBs) affect 
the risk of incident active tuberculosis disease. MethOds: A nested case control 
study was carried out using the claims data from National Health Insurance Research 
Database of Taiwan between January 1997 and December 2011. Index date referred to 
the first date of TB diagnosis. Patients with CCBs exposure were defined by receiving ≧ 
7 days of prescription ending in 3 different time frames. Current use refers to prescrip-
tion that ended within 30 days of the index date. Multivariate regression and a disease 
risk score (DRS) technique were used to calculate risk of active TB disease. Results: 
InfeCtIon – Clinical outcomes studies
PIn1
MAlArIA dIAGnosIs And treAtMent PrACtICe folloWInG IntroduCtIon 
of rAPId dIAGnostIC test In seleCted heAlth Posts of AdAMA WoredA, 
eAst sheWA zone, oroMIA reGIon,CenterAl ethIoPIA
Ahmed SM, Tefera M
Jimma University, Jimma, Ethiopia
Objectives: To assess malaria diagnosis and treatment practices follow-
ing introduction of rapid diagnostic test in Adama district health posts, central 
Ethiopia. MethOds: A Cross-sectional study was conducted from January 24 to 
February 9, 2014 among febrile patients, and caretaking health workers to determine 
the perceptions and practices related to rapid diagnostic tests (RDTs). Moreover, the 
treatments prescribed were assessed at the selected Health posts. From the total of 
37 health posts in Adama district, 10 health posts were selected by simple random 
sampling technique. All the patients who visited the health posts during the study 
period and all health service providers working in the selected health posts were 
included in the study. Results: The survey was undertaken at ten health posts 
which use RDT for parasitological confirmation. Twenty health workers and 104 
patients were interviewed at health posts. Eighty three patients (79.8%) were seen in 
health posts with available parasite based diagnostic test (i.e. RDT)) and 21(20.2%) in 
facilities without RDT. The overall malaria positivity rate was 48(57.8%). Anti–malaria 
drugs were prescribed to all 48(100%) patients with positive RDT and to 19(54.3%) of 
RDT negative patients. Among non-tested patients, anti-malaria drugs were given 
to 12(57.1%), with a higher prescription rate in health posts without RDTs results. 
Among 104 patients presenting with fever or history of fever, 64(61.5%) were pre-
scribed with antibiotics and anti-pain. cOnclusiOns: Findings from this study 
show that over prescription with anti-malarial drugs is common in Adama district 
health posts. The use of rapid malaria diagnostics was also associated with higher 
prescription of antibiotics among patients with negative test results. The Adama 
district health office should provide on job and other capacity building trainings for 
health workers on RDTs, the diagnosis and management of other causes of fever 
and the importance of adhering to test results.
PIn2
effeCt of trAnsfer fACtor on the reduCtIon of the nuMber of 
ePIsodes of reCurrent InfeCtIons In Adult And PedIAtrIC PAtIents 
froM A MultICentre observAtIonAl study
Marusakova E1, Hroncova D2, Keszegh J3
1Medical Care Consulting Ltd., Lozorno, Slovak Republic, 2InovaHealth Ltd., Suchohrad, Slovak 
Republic, 3Neox Ltd., Bratislava, Slovak Republic
Objectives: To assess the effect of human leukocyte transfer factor for paren-
teral use (TF) in adult and pediatric patients suffering from cellular immunode-
ficiency (CID) in whom TF had been indicated for treatment of respiratory and/
or urinary tract infections, prostatitis and/or vulvovaginitis episodes. MethOds: 
Observational multicenter retrospective study in subjects being treated with TF in 
the period from September 2012 to April 2013 in Slovakia. The primary objective 
was to evaluate the effectiveness by assessment of the number of documented 
infections over one year since the treatment began as compared to the last year 
of the pre-treatment period. Moreover, the resource use and QoL assessment was 
conducted using EQ-5D. Results: The sample (98 analyzed patients) in 9 centers 
was predominantly female (75.5%) and the average age was 46.6, with a range of 
7 to 82. The most common recurrent episodes were respiratory tract infections 
occurring 5 (472/96 with infection) times at average in the year before TF initia-
tion (96 patients), followed by urinary tract infections (n= 38) and vulvovaginitis 
episodes. The significant reduction was observed in all three types of recurrent 
infections after treatment with TF (prostatitis not analyzed). Respiratory tract infec-
tions where reduced from 5 to 2 a year after, in contrast to the period before initia-
tion of TF application (p< 0.001). Significant reduction was achieved in urinary tract 
infections and vulvovaginitis episodes (p< 0.001). Reduction was accompanied by a 
lower resource use, measured by the need of antibiotics and hospitalizations. The 
median of parenteral TF doses was 8 injections for a full study period (maximum 
2 years). cOnclusiOns: The conducted study showed that leukocyte human TF 
helps to reduce recurrence of episodes of infections in adult and pediatric patient 
with CID. Besides clinical and resource outcomes, the contribution of this study is 
the elicitation of utility values for CID of different severity.
PIn3
systeMAtIC revIeW And MetA-AnAlysIs of effICACy And sAfety of 
sIMePrevIr And sofosbuvIr for hCv GenotyPe 1 InfeCtIon
Borba HH, Wiens A, Perlin CM, Pontarolo R
Universidade Federal do Paraná, Curitiba, Brazil
Objectives: To evaluate the efficacy and safety of the second-wave direct-act-
ing antivirals simeprevir and sofosbuvir in patients with HCV genotype 1 infec-
tion through a systematic review and meta-analysis of randomized clinical trials 
(RCTs). MethOds: Electronic searches were performed in databases MEDLINE, 
International Pharmaceutical Abstracts (IPA), Cochrane Library, SCIELO and Scopus. 
Statistical analyses were executed using the software Review Manager version 
5.3. Results: 774 articles were identified, of which 10 RCTs were selected for data 
extraction and statistical analysis. Simeprevir 100 mg promoted better RVR and 
SVR24 Resultsthan placebo, and simeprevir 150 mg was superior to placebo for the 
following outcomes: RVR, SVR12, SVR24, SVR12 rates according to METAVIR score 
for the subgroups F0-F2, F3 and F4, SVR12 rates according to HCV genotype for both 
genotype 1a and genotype 1b, SVR12 rates for HCV genotype 1a without baseline 
Q80K and SVR12 according to IL28B genotype for CC, CT and TT. More viral relapse 
events were observed in the placebo group, for both evaluated doses. There were no 
significant differences for all of the evaluated safety outcomes between the sime-
previr 100 mg and the placebo groups, and for almost all evaluated safety outcomes 
between the simeprevir 150 mg and placebo groups. Sofosbuvir promoted better 
